Incyte — Apr 28, 2026 release

6 Cash, cash equivalents and marketable securities position Cash, cash equivalents and marketable securities as of March 31, 2026, were $4.0 billion, compared to $3.6 billion as of December 31, 2025. 2026 Financial Guidance Incyte’s guidance for the fiscal year 2026 is summarized below. Incyte is reaffirming its guidance across all categories. Current Total net sales $4,770 - $4,940 million Jakafi net sales (1) $3,220 - $3,270 million Opzelura net sales (2) $750 - $790 million Hematology and Oncology net sales (3) $800 - $880 million Total GAAP R&D and SG&A operating expenses $3,495 - $3,675 million Total Non-GAAP R&D and SG&A operating expenses (4) $3,205 - $3,375 million 1 Includes the initial launch of Jakafi XR 2 Includes net sales for moderate atopic dermatitis in Europe which is anticipated to be approved in the second half of 2026. 3 Pemazyre ® (pemigatinib) in the U.S., Canada, Europe, Japan, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America (LatAm); Niktimvo and Monjuvi in the U.S.; Zynyz in the U.S., Europe and Japan; Iclusig ® (ponatinib) in Europe and MEA; and Minjuvi (tafasitamab) in Canada, Europe, Japan, APAC, MEA and LatAm. 4 Adjusted to exclude the estimated cost of stock-based compensation. Conference Call and Webcast Information Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13759527. If you are unable to participate, a re